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Abstract
Background Recently, we demonstrated that losartan reduced
the aortic root dilatation rate (AoDR) in adults with Marfan
syndrome (MFS); however, responsiveness was diverse. The
aim was to determine the role of transforming growth factor-β
(TGF-β) as therapeutic biomarker for effectiveness of losartan
on AoDR.
Methods Baseline plasma TGF-β levels of 22 healthy con-
trols and 99 MFS patients, and TGF-β levels after 1 month of
losartan treatment in 42 MFS patients were measured. AoDR
was assessed by magnetic resonance imaging at baseline and
after 3 years of follow-up.
Results Patients with MFS had higher TGF-β levels
compared with healthy controls (121 pg/ml versus 54
pg/mL, p=0.006). After 1 month of therapy, losartan
normalised the TGF-β level in 15 patients (36%); the
other 27 patients (64%) showed a significant increase of
TGF-β. After 3 years of losartan therapy, patients with
a decrease in TGF-β had significantly higher AoDR
compared with patients with increased TGF-β (1.5
mm/3 years versus 0.5 mm/3 years, p=0.04). Patients
showing a decrease in TGF-β after losartan therapy had
significantly elevated baseline TGF-β levels compared
with patients with increased TGF-β (189 pg/ml versus
94 pg/ml, p=0.05).
Conclusion Patients responding to losartan therapy with
a reduction of the plasma TGF-β level had higher
baseline TGF-β levels and a higher AoDR. Most likely,
TGF-β levels may be considered to be a readout of the
disease state of the aorta. We propose that increased
angiotensin II is the initiator of aorta dilatation and is
responsible for increased TGF-β levels in MFS. The
concept of TGF-β as initiator of aortic dilatation in
MFS patients should be nuanced.
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Introduction
Aortic root dilatation is a hazardous complication in patients
with Marfan syndrome (MFS), an heritable connective tissue
disorder equally prevalent all over the world [1, 2]. MFS is
caused by mutations in the FBN1 gene [3]. These mutations
induce abnormal or deficient fibrillin-1 protein affecting the
structural integrity of the vascular extracellular matrix, and
have been described to enhance the release of transforming
growth factor-β (TGF-β) [4]. We have shown that plasma
TGF-βwas indeed elevated inMFS patients, which correlated
to increased aortic root diameter and aortic root dilatation rate
(AoDR) [5].
Current treatment comprises prophylactic aortic root re-
placement and β-blocker therapy, which has significantly
improved the life expectancy of patients with MFS. However,
cardiovascular complications remain a problem [6, 7]. In a
MFS mouse model, losartan was superior to β-blocker thera-
py in decreasing AoDR. This losartan effect was attributed to
reduced TGF-β expression, which was mimicked by treat-
ment with neutralising TGF-β antibodies [8].
These findings in mice have resulted in the initiation
of multiple studies assessing the effect of losartan on
AoDR in MFS patients. Recently, we demonstrated that
losartan reduced AoDR in a randomised and prospective
cohort of adult patients with MFS (COMPARE trial) [9,
10]. In addition, a small study in 20 children revealed
beneficial effects of losartan on AoDR. [11, 12] How-
ever, the responsiveness to losartan treatment was di-
verse, which may depend on variability in expression
and release of TGF-β. In order to determine the role of
TGF-β as a therapeutic biomarker for the effectiveness
of losartan therapy on AoDR, we performed a sub-study
of the COMPARE trial and revealed that TGF-β is an
indirect effector of aortic dilatation.
Effect of losartan therapy on plasma TGF-β levels
For this sub-study we measured baseline TGF-β levels of
99 MFS patients, all monitored by the Academic Medical
Centre Amsterdam, of whom 55 were randomised to
100 mg losartan and 44 to no losartan. In 42 patients
on losartan therapy, plasma TGF-β levels were also
assessed after 1 month of treatment. We recruited 22
‘healthy controls’ in whom MFS was definitely ruled out
(Fig. 1a). In order to determine AoDR, MFS patients
underwent magnetic resonance imaging of the aorta at
baseline and after 3 years of follow-up.
Despite inter-laboratory variations in TGF-β measure-
ments throughout the medical world, our TGF-β
measurements show that MFS patients had significantly
higher TGF-β levels compared with healthy controls
(121 pg/ml versus 54 pg/mL, p=0.006), which is in line
with our previous results [2]. Surprisingly, 1 month of
losartan therapy did not reduce circulating TGF-β levels
(101 pg/mL; 95% CI: −27:229 pg/mL; p=0.12) (Fig. 1b).
TGF-β levels were only normalised to the control level in
15 of the 42 patients (p=0.26). In the remaining 27
patients TGF-β did not decrease after one-month losartan
therapy, and showed a significantly higher TGF-β com-
pared with the healthy controls (292 pg/ml versus 54 pg/
mL, p=0.028). Unexpectedly, after 3 years of losartan
therapy, patients with a decrease in TGF-β had a signif-
icantly higher AoDR compared with patients without re-
duced TGF-β levels (1.5±0.8 mm/3 years versus 0.5±1.2
mm/3 years, respectively; p=0.04). In addition, 91% of
the patients with a decrease in TGF-β showed a signifi-
cant increase in AoDR despite losartan therapy, compared
with 33% of the patients with increased/stable TGF-β
levels after losartan (p=0.013) (Fig. 1a,b). In order to
explain these unexpected results, we compared baseline
characteristics between these groups. Patient groups were
comparable, with the exception of baseline TGF-β levels
(Table 1). Patients showing a decrease in TGF-β after losartan
therapy had significantly elevated baseline TGF-β levels
compared with patients who did not show this decrease (189
±166 pg/ml versus 94±113 pg/ml, p=0.05) (Fig. 1b). Inter-
estingly, we found a linear association between the change in
TGF-β level and the increase in AoDR in patients using
losartan therapy (r=0.47, p=0.02) (Fig.1c). This effect could
not be ascribed to β-blocker therapy, because β-blocker ther-
apy +/− losartan therapy was not different at any level (data
not shown).
Revised role of TGF-β in aortic aneurysms in Marfan
syndrome
This sub-study highlights a paradoxical topic of TGF-β in the
pathogenesis of MFS. Although 3 years of losartan therapy
reduces the overall AoDR in MFS patients [9], only one-third
of MFS patients responded by a reduction of plasma TGF-β
after 1 month of losartan therapy. These responders had ele-
vated baseline TGF-β levels and an increase in AoDR after
3 years, despite losartan therapy. Considering treatment with
100 mg losartan is a sufficient dose to reduce AoDR in MFS
[9], and assuming that one-month treatment is sufficient to
initiate a TGF-β response, we have three possible explana-
tions for our findings.
The first explanation for the fact that losartan did not reduce
overall TGF-β levels is that TGF-β is a readout of the diseased
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state of the aorta. Losartan did reduce TGF-β levels in a
subgroup of MFS patients, yet these patients revealed a higher
AoDR after 3 years of therapy. This increase in AoDR may be
explained by the elevated baseline TGF-β levels and the
slightly, but non-significant larger aortic root dimension at
baseline (45±4 mm versus 43±6 mm, p=0.215). Both factors
are associated with an increase in AoDR. [5] These results
suggest that elevated plasma TGF-β is a marker for aortic
damage, such as fibrosis, rather than the initial cause of aortic
dilatation.
Fig. 1 a Flowchart shows an
overview of Marfan syndrome
patients and controls. Plasma
TGF-β was analysed by ELISA
(R&D Systems). b In 15 of the 42
MFS patients losartan normalised
plasma TGF-β levels to that of
controls. In 27 ofMFS patients no
reduction of plasma TGF-β was
observed. c Decrease in TGF-β
level is associated with an
increase in AoDR in patients
using losartan therapy (r=0.47,
p=0.02). Linear regression
analysis was used. AoDR=Aortic
root dilatation rate; TGF-β=
transforming growth factor β
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A second explanation for the variable response of TGF-β
to losartan therapy comprises the multitude of FBN1 muta-
tions. At present, more than 2900 different mutations have
been described in the Universal Mutation Database [13]. Most
FBN1 mutations result in expression of mutated fibrillin-1
proteins, which are improperly folded. The abnormal
fibrillin-1 protein may have a dominant-negative effect on
the structure of the extracellular fibrillin network when it
interacts with normal fibrillin-1 protein of the non-mutated
allele and other extracellular matrix proteins. Both the strength
of the fibrillin-1 matrix may be changed as well as the release
of TGF-β that is captured in the fibrillin-1 network.Mutations
in one of the seven TGF-β binding protein-like (TB) domains
of the FBN1 gene may especially alter TGF-β levels.
Other FBN1 mutations will lead to reduced fibrillin-1 pro-
tein levels as a result of deletion of the entire FBN1 gene on one
allele [14] or for example upon deletion of the first exon of
FBN1 (such that the mRNA is not translated), causing
‘haploinsufficiency’. The reduced level of normal fibrillin-1
protein presumably results in a thinner fibrillin-1 matrix in the
vasculature and thus in reduced aortic wall strength. In such
patients, angiotensin II (AngII) activation may be increased to
maintain normal blood pressure. The AngII-mediated signal-
ling cascade is a common inducer of TGF-β production in the
vessel wall and thus involved in the increased plasma TGF-β
levels in these patients. Blocking the AngII receptor-1 (AT1)
with losartan will diminish TGF-β production as well as other
AngII-mediated detrimental processes in the vessel wall such as
blood pressure increase, enhanced pro-inflammatory responses,
myofibroblast differentiation and reactive oxygen species
(ROS) generation. Therefore, we hypothesise that in patients
with an FBN1mutation leading to haploinsufficiency, the effect
of losartan on aortic dilatation is better compared with patients
with a dominant-negative mutation. We anticipate that genetics
plays a critical role in the TGF-β response to losartan [15].
A third explanation for the variable TGF-β response to
losartan therapy comprises variation in the abundance of AT1
expression or activity, or by polymorphisms in the renin-
angiotensin-aldosterone system (RAAS). Increased AngII-
mediated signalling as a result of this type of polymorphisms
will coincide with increased TGF-β production. A number of
polymorphisms have been identified in RAAS that are asso-
ciated with aneurysms. For example, the ACE deletion/
insertion polymorphism is significantly associated with an
increased risk for thoracic aortic aneurysm formation [16].
Angiotensin II as a cause of aortic dilatation?
InMFSmice, direct inhibition of TGF-βwas effective against
AoDR. [8] However, in most studies TGF-β signalling has
been extrapolated from the abundance of Smad2 activation
(pSmad2) in the dilated aortic tissue [17]. Smad signalling is
best known from its role in the TGF-β-induced signalling
cascade, where it transfers the extracellular TGF-β signal to
the nucleus to act as a transcription factor and to regulate gene
expression [18]. Before birth, TGF-β is essential for the
development of the cardiovascular system [19]. In later life,
TGF-β is expressed in reaction to injury, mediating a fibrotic
response for repair. This accentuates the possibility that
TGF-β is a result and not the cause of aortic damage. Inter-
estingly, AngII can induce Smad2 activation directly through
its receptor AT1 [20, 21], as well as indirectly by enhancing
TGF-β expression (Fig. 2). Thus, increased levels of TGF-β
and pSmad2 levels in MFS may both result from increased
AngII-mediated signalling. When AngII is considered a pri-
mary cause of aortic disease in MFS, other detrimental AngII-
mediated pathwaysmay be responsible for initiation of arterial
damage (Fig. 2). Excessive TGF-β signalling subsequently
leads to secondary disease progression.
In mice, chronic infusion of AngII is known to affect the
integrity of the vasculature resulting in aneurysms in the
ascending and descending aorta [22, 23]. We propose that
the beneficial effect of losartan on AoDR in MFS mice and
patients [5, 6, 8] is obtained through inhibition of the
unfavourable AngII-mediated signalling cascades, involving
TGF-β synthesis and pSmad2 signalling, blood pressure






MFS patients with: (n=15) (n=27) p-value
Clinical features
Mean age (SD) 38 (10) 35 (11)
Sex (male) 7 (47) 18 (67)
Baseline TGF-β level* 189 (166) 94 (113) 0.05
Cardiovascular
AoR dilatation 15 (100) 22 (81)
Mean AoR diameter (SD) 45 (4) 43 (6)
AoR operation 4 (27) 9 (33)
Mean age AoR operation (SD) 31 (11) 31 (15)
MV prolapse 12 (80) 17 (63)
MV repair 1 (7) 3 (11)
FH of dissection 6 (40) 12 (44)
Dilatation of distal aorta 2 (13) 3 (11)
β-blocker 10 (67) 21 (78)
dosage >100 mg 5 (33) 14 (52)
dosage <100 mg 5 (33) 7 (26)
Values are given in absolute numbers (percentage) if not otherwise
indicated
SD: standard deviation; AoR: aortic root; MV: mitral valve; FH: family
history
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increase, myofibroblast differentiation, ROS generation and
pro-inflammatory responses [22, 24].
Limitations
Wewish to emphasise that the power of our study was limited,
therefore a prospective trial with a larger patient cohort is
needed to confirm our results. Furthermore, TGF-β levels
are known to vary between different laboratories. In order to
prevent these variations, we collected plasma samples and
performed all TGF-β measurements in the same laboratory
at the same time. Finally, it would have been interesting to
have the follow-up TGF-β measurements after 3 years of
losartan therapy. Despite these study limitations, our results
are in line with our previous results [5].
Conclusion
In conclusion, the variable effect of losartan on plasma TGF-β
levels probably reflects, at least in part, the heterogeneity in
FBN1 mutations or RAAS modifiers. We showed that MFS
patients who responded with a decrease in plasma TGF-β
level during losartan therapy had higher baseline TGF-β
levels. Most likely, TGF-β levels may be considered to be a
readout of the disease state of the aorta. Significantly, the
effectiveness of losartan on the AoDR in MFS patients [6, 8]
proves that Ang II-mediated signalling is crucial in the vascu-
lar pathology of MFS. We propose that increased AngII
signalling is the initiator of aorta dilatation and is responsible
for the increased TGF-β levels in MFS. The concept of
TGF-β as the initiator of aortic dilatation in MFS patients
should be nuanced now it is clear that AngII-mediated signal-
ling is instructive and affects more than just TGF-β levels.
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Fig. 2 Schematic overview of proposed mechanism involving AngII-
and TGF-β-mediated signalling in aortic dilatation in MFS. AngII in-
duces a number of detrimental processes via AT1 when (chronically)
elevated. AngII directly activates Smad2 (pSmad2) and increases TGF-β
production, which can be secreted and subsequently binds to its cell
surface receptor and thereby increases Smad2 activation further. Losartan
blocks AT1 and thus inhibits AngII-mediated signalling including Smad2
activation, TGF-β production, blood pressure increase, pro-inflammatory
responses, myofibroblast differentiation and ROS generation. AngII=
angiotensin II; AT1=angiotensin II receptor type 1; pSmad2=phosphor-
ylated Smad2; ROS=reactive oxygen species; TGF-β=transforming
growth factor β
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Abbreviations
AngII Angiotensin II
AngII is a peptide hormone that causes vaso-
constriction and a subsequent increase in blood
pressure
AngII is part of the RAAS
AoDR Aortic root dilatation rate
AoDR is the rate the aortic root dilates in
grown-up MFS patients in mm/year
AT1 Angiotensin II type 1 receptor
AT1 is a receptor with AngII as its ligand and is
subsequently responsible for the signal transduc-
tion leading to vasoconstriction. AT1 is part of the
RAAS and is blocked by AT1-blockers, including
losartan
MFS Marfan syndrome
MFS is a connective tissue disorder and diag-
nosed according to the Ghent criteria of 2010 [25]
RAAS Renin-angiotensin-aldosterone system
RAAS is a hormone system that regulates blood
pressure and water (fluid) balance
ROS reactive oxygen species
ROS are a natural by-product of the oxygen
metabolism. ROS levels can increase dramatically
during times of environmental stress, and may
subsequently damage cell structures
pSmad2 phosphorylated Smad2
pSmad2 is the activated form of Smad2, a trans-
ducer protein that mediates the signal of TGF- β
TGF-β transforming growth factor-β
TGF-β is a multifunctional peptide that controls
proliferation, differentiation and other functions in
many cell types, and is thought to be the detrimen-
tal cause of MFS
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